ERBB2 and breast cancer: Stereotactic radiotherapy (HR 0.49 95 %CI 0.30–0.79) and whole brain irradiation (HR: 0.58, 95 %CI: 0.42–0.80), endocrine therapy in patients with HR + BC (HR: 0.31, 95 %CI: 0.21–0.45) as well as HER2-targeted therapy for patients with HER2+ BC (HR 0.41, 95 %CI: 0.25–0.68) were associated with a significantly longer survival.